-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 14th, GenScript issued an announcement to enter into binding contract specifications with investors regarding Probio Cayman (an indirect wholly-owned subsidiary of the company, GenScript Boom Bio) proposed a round of financing
.
Accordingly, GenScript Bio will subscribe through its subsidiary Probio BVI before the completion of Probio to subscribe for US$70 million convertible bonds that can be converted into Probio shares
It is reported that as of the date of this announcement, Probio Cayman is indirectly wholly-owned by GenScript Biotech through its wholly-owned subsidiary Probio BVI
.
After Probio is completed, Probio BVI's equity in Probio Cayman will be diluted to 82.
The proceeds from the Series A financing are intended to meet the general working capital needs of Probio Cayman's main business operations